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ABstRACt
In this article, a group of experts in headache management of the Brazilian Headache Society developed through a consensus strategic 
measurements to treat a migraine attack in both the child and the adult. Particular emphasis was laid on the treatment of migraine in 
women, including at pregnancy, lactation and perimenstrual period.
Keywords: headache, migraine, treatment, pain medication, crisis.
Resumo
Neste artigo um grupo de especialistas no tratamento de cefaleia da Sociedade Brasileira de Cefaleia através de um consenso elaborou 
medidas estratérgicas para tratar uma crise de migrânea tanto na criança como no adulto. Uma enfase particular foi dada no tratamento 
da migranea na mulher, incluindo gravidez, lactação e período perimenstrual.
Palavras-chave: cefaleia, enxaqueca, tratamento, analgésico, crise.
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The approach to the patient suffering from migraine 
begins by the clinical history, a crucial step, once the di-
agnosis is essentially clinical. Migraine diagnosis is based 
on the crisis characteristics and must meet the criteria 
provided by the International Classification of Headache 
Disorders - ICHD-3 beta. Additional tests are reserved 
when differential diagnosis of secondary headaches is re-
quired. It is important to identify comorbidities, among 
which emotional and anxiety disorders and high blood 
pressure stand out.
Treatment of a migraine attack includes pharmacologi-
cal and non-pharmacological measures. All migraine crisis 
should be treated, regardless of their intensity.
This article aims to develop a consensus with experts 
from the Brazilian Headache Society and the Scientific 
Department of Headache of the Brazilian Academy of 
Neurology on how migraine attack treatment is recommend-
ed. We will add some recommendations on general and ed-
ucational measures and to the treatment of comorbidities, 
although they are not relate specifically to the crisis of mi-
graine, for the importance of these procedures in reducing 
the frequency of these episodes of pain.
GeneRAl And eduCAtionAl meAsuRes
Patients should be warned about the triggering factors of 
crises, so that they can identify these factors and thereby re-
duce the frequency of migraine episodes, at least in part. The 
triggering factors are multiple and individual. Each patient 
must check potential triggering factors for their crises with 
the assistance of the doctor. Among the most common are 
the stress, the emotions, inconsistent sleep schedules (exces-
sive hours of sleep, sleep deprivation or sleeping outside the 
usual time), the suppression of meals or prolonged fasting, 
excessive regular use of caffeine, alcohol intake and specific 
foods. The use of food lists to be avoided should not be en-
couraged, when only foods identified as crises triggering fac-
tors should be discontinued.
Guidance on the risks of self-medication, and especial-
ly on the risk of excessive use of abortive medications is of 
great importance1.
Comorbidities should always be treated and, if applicable, 
the patient should be referred to other professionals of spe-
cific areas.
Use of a diary for recording crises should be encouraged 
in order to not underestimate or overestimate the frequency, 
intensity and duration of migraine crises.
Patients and their families should be clarified, in an 
accessible language, about the neurobiological and ge-
netic nature of the disease, the diagnosis criteria and be 
warned on the factors that can modify the natural course 
of the disease2.
non-PhARmAColoGiCAl meAsuRes
Simple measures such as resting in a calm, airy and low 
light environment are known to be effective. To sleep during 
a crisis may also be a source of pain relief3. The use of cold 
compresses on the forehead and temples is reported by many 
to be useful.
There is no conclusive evidence on the use of addition-
al treatments, such as relaxation techniques, chiropractic, 
transcutaneous electrical nerve stimulation (TENS), mas-
sage and cold compresses. However, coping techniques 
should be encouraged.
Studies on the use of acupuncture to treat migraine have 
shown low therapeutic efficacy4. There is solid evidence dem-
onstrating the ineffectiveness of homeopathy in the treat-
ment of a crisis.
Recently, invasive and non-invasive neurostimulation 
therapy to treat migraine crises, such as transcranial magnet-
ic stimulation, occipital nerve stimulation and transcutane-
ous supraorbital therapy have been described. Although with 
positive results in some patients, there are no sufficient data 
to its recommendation5.
PhARmAColoGiCAl meAsuRes
Treatment of migraine crises should consider individual 
features, as migraine is known as a complex disease, involv-
ing multiple characteristics that vary from one person to an-
other and that influence the treatment outcome.
Drugs should be chosen taking into account the 
history of each patient (previous results, allergies, 
contraindications, comorbidities).
The prescription must include all required information 
and be clear as to when to use, in which doses, when to re-
peat or change doses.
The treatment can be done with specific and/or non-
specific drugs. The specific drugs are the triptans and ergot 
derivatives. The nonspecific drugs are the simple analgesics 
and the nonsteroidal anti-inflammatory drugs (NSAIDs). The 
concomitant use of antiemetic, neuroleptic and corticoste-
roid drugs may be required. Opioids should be avoided.
Triptans are agonists to the serotonin 5HT-1b, 1d-5HT 
and 5HT-1f receptors. Four medications in this class are 
sold in Brazil: sumatriptan, naratriptan, zolmitriptan 
and rizatriptan.
Sumatriptan, a pioneer drug, is the one that comes with 
more presentation forms: 25 mg, 50 mg and 100 mg tab-
lets, 6 mg subcutaneous injection, 10 mg/dose nasal spray. 
The subcutaneous use is the one with greater efficiency and 
speed of action, followed by the nasal route. These two forms 
are particularly useful in patients showing the early symp-
toms of nausea and vomiting appearing in the crisis. In order 
to treat the crises that allow the oral administration, a 50 mg 
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dose should be tried. If response is unsatisfactory, it should 
made use of an administration of 100 mg. For any of the dos-
age forms for an unsatisfactory response, one can repeat the 
treatment after 2 hours. The maximum daily doses for each 
formulation are subcutaneous injection - 20 mg (two admin-
istrations); nasal route - 40 mg; oral route - 200 mg.
Naratriptan is marketed in tablets of 2.5 mg. This drug 
shows a disadvantage when compared to Sumatriptan, as 
it is less potent and has a slower onset of action, but with 
the advantage of being one of the triptans among those sold 
in Brazil with the best profile of tolerability, and a more pro-
longed action. It also seems to show a recurrence rate of less 
pain than the sumatriptan.
Rizatriptan is the most powerful drug among the oral trip-
tans. In Brazil, it is marketed only in tablets of 10 mg. Patients 
who use rizatriptan respond to the treatment (i.e., they go from 
a status of strong or moderate pain to mild pain or no pain) and 
pain remission in less time than when using other oral trip-
tans. There is an interaction between rizatriptan and propran-
olol, so that this association causes a more rapid and greater 
concentration of rizatriptan. In the association with these two 
drugs, the dose of rizatriptan should be reduced to 5 mg. The 
presentation of 5 mg tablets is no longer available in our coun-
try. After a first administration of 10 mg or 5 mg (indicated only 
when the patient is using it concomitantly with propranolol), 
the medicament may be repeated, if required, after two hours. 
The recommended maximum daily dose is 30 mg/day.
Zolmitriptan is a drug of good oral bioavailability, with 
similar results to that of the sumatriptan. It is marketed in 
the form of conventional tablets and oral-dispersible at a 
concentration of 2.5 mg per dose.
Response to triptans is not uniform. It is assumed that 
30% of patients do not respond satisfactorily, but a patient 
who had failure with one of them, can be successful with the 
other. Triptans have good toleration. The most common ad-
verse effect is drowsiness. Some patients feel chest, nuchal or 
cranial tightness few minutes after using these substances. 
This adverse effect is most common to the subcutaneous su-
matriptan, but may occur in any of them. Although daunt-
ing to some, it is a harmless symptom, and patients should 
be warned of the possibility of their occurrence. This group 
of drugs is contraindicated to patients with a history of isch-
emic heart disease and ischemic stroke.
It must be remembered that repeating the triptan can be 
useful for relapses, being observed the recommendations on 
the maximum doses.
Patients who respond only partially to triptans or to 
NSAIDs can have a better response when there is a combina-
tion of these classes of substances.
The ergot derivatives, in addition to acting on serotonin-
5HT 1b and 5HT-1D receptors, they can also act on cholin-
ergic, adrenergic and muscarinic receptors, which can cause 
a greater range of adverse effects. The only ergot derivative 
in use in Brazil is the dihydroergotamine, which is available 
only in the form of fixed combinations (associations with dif-
ferent substances, such as dipyrone or paracetamol, caffeine 
or metoclopramide), which may constitute in an additional 
limitation. The dihydroergotamine has an erratic oral absorp-
tion, and it is not possible to foresee which serum concen-
tration will be achieved, also having the disadvantage of en-
hancing nausea and vomiting in some patients.
Since triptans and ergot derivatives act in the same sero-
tonin receptors, the concomitant use of these drugs is contra-
indicated. When a patient has already used a triptan, he can 
only use dihydroergotamine six hours later. On the other hand, 
after the initial intake of dihydroergotamine a triptan can only 
be used after 24 hours due to the longer half-life of this drug.
Isometheptene is a vasoconstrictor drug, marketed in as-
sociation with dipyrone and caffeine. It is useful in patients 
with low-intensity migraine pain.
Some forms of migraine with aura, such as the mi-
graine with brainstem aura (old basilar migraine), hemi-
plegic migraine and migraine with prolonged aura are 
contraindicated to be used with triptans, dihydroergota-
mine or isometheptene.
Simple analgesics (dipyrone and acetaminophen) and 
NSAIDs are useful. Paracetamol is a low potent drug. It is 
used more in people who, by allergies or other reasons, can-
not use an NSAID or a dipyrone. The recommended dose for 
adults is 1,000 mg, which may be repeated, if required, up to 
the limit of 4 grams per day. It is a good option in the elderly 
patients, to whom the risk of the use of an NSAID is higher. 
The association with caffeine potentiates its effect. The as-
sociation with codeine or tramadol is little efficient, and en-
tails a risk of dependence and chronicity of migraine, and it 
is not recommended.
Dipyrone is a drug banned in many countries because of 
the risk of agranulocytosis. This fear seems exaggerated, once 
the estimate is that there will be one case per 1 million us-
ers. The risk of death for the use of dipyrone is 0.2 per million 
users, against 0.25 paracetamol and about 6.0 naproxen and 
diclofenac. Dipyrone can be used at doses of 1 or 2 grams in 
migraine crises, and may reach 3.0 grams.
NSAIDs are widely used and effective drugs. They consti-
tute a pharmacological group of very varied characteristics. 
In the treatment of migraine, drugs of rapid action and short 
or intermediate half-life are the most indicated.
Opioids should be avoided. Studies on the paracetamol-co-
deine combination showed no superiority over acetaminophen 
alone. Meperidine, still widely used in Brazil, has normeperi-
dine, a neurotoxic metabolite, and its use should be proscribed. 
Although isolated studies on tramadol have shown some ther-
apeutic effect, there are more effective drugs that have no risk 
of abuse and dependence, so its use is discouraged.
Dopamine antagonists with antiemetic effect (meto-
clopramide, domperidone and bromopride) are useful 
even in the absence of nausea. The gastroparesis at a mi-
graine crisis justifies its use. The metoclopramide and 
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bromopride cross the blood-brain barrier with central and 
peripheral actions. There is also evidence that the meto-
clopramide has an anti-migraine action, and it may how-
ever, cause extrapyramidal symptoms. In this situation, 
domperidone is a good option.
stRAteGies: (1) steP-By-steP tReAtment 
veRsus stRAtified And (2) eARly tReAtment
Strategies based on pain intensity – According to pain 
intensity, the migraine crisis is classified in low (does not 
interfere with daily activities), moderate (difficult, but 
do not prevent) and strong (disabling). The drugs for cri-
ses treatment (specific and nonspecific) can be used in 
different ways:
1) Step by step in different crises – As there is a great vari-
ability in the therapeutic response between different patients, 
the initial guidance in this case is to treat a sequence of crises 
with no specific drugs (simple analgesics or NSAIDs). If treat-
ment is ineffective, subsequent crises should be treated with 
specific drugs (dihydroergotamine or triptans)6,7.
2) Step-by-step in the same crisis – Scaling in the choice of 
drugs can be used in the same crisis, meaning that if the first 
action is not satisfactory, specific drugs can be administered 
in the same migraine crisis6,7.
3) Stratified – During the clinical history interview, the 
characteristics of previous crises, particularly the inten-
sity of pain, are recorded in order to set a treatment strat-
egy. In patients whose crises are usually mild to moder-
ate in intensity, less potent drugs would be used (simple 
analgesics or NSAIDs). In patients whose crises are usu-
ally moderate to strong, more potent drugs (i.e., triptans) 
would be the first choice. The stratified approach treats 
patients with greater functional impairment with specif-
ic drugs earlier. Therefore, a faster remission, self-medi-
cation and analgesic medication overuse reduction is 
acheived8. Regarding the economic impact, although the 
stratified strategy show a higher direct cost, its effective-
ness leads to a smaller reduction in the individual’s pro-
ductivity, resulting in lower total cost9,10.
4) Strategy based on the evolution of the crisis – The first 
trials to test the effectiveness of triptans in migraine crisis 
showed that the result in moderate or strong intensity cri-
sis was insatisfactory11. The need for a drug that produces 
a quick and lasting relief and low recurrence rate12 led to a 
change in the approach, with early take of triptan. The best 
response to this new recommendation (taken in the first 
hour) was evident13-16.
Despite the advantages of early triptans use, some factors 
may hinder this strategy: crises that start during sleeping8, 
misuse in a tension-type headache17,18 and stimulus on the 
overuse of analgesics8.
menstRuAl miGRAine (inCludinG 
miniPRoPhylAxis), PReGnAnCy And 
menoPAuse
Migraine has peculiar characteristics in the female popula-
tion, with regard to psychosocial, hormonal, genetic, response 
to environmental stress and work, perception of pain, contra-
ceptive use, pregnancy, breastfeeding and menopause. The mi-
graine attacks are more frequent, intense, long and disabling 
in women, justifying different treatment strategies. The use of 
contraceptives may influence the clinical course of migraine 
( frequency, intensity), but handling crisis remains unchanged.
tReAtment of miGRAine CRisis in women
migraine and menstrual cycle
Among the migraine crises, 35% to 54% women reported 
to have crises during the menstrual period, that in general, 
are characterized by:
• Longer duration;
• Increased proportion of recurrence;
• Increased association with disability;
• Increased resistance to treatment;
• Association with dysmenorrhea and premenstrual 
dysphoric disorder.
The treatment of migraine crises associated with the men-
strual period is similar to the other crises, except for plain men-
strual migraine, when a miniprophylaxis is favored (5-7 days) 
with NSAIDs, triptans, magnesium, vitamin E, pyridoxine and 
hormones ( see Figures 1, 2 and 3 and Tables 1, 2 and 3).
migraine in pregnancy and during lactation
Pregnancy can give rise to changes to the previous pattern of 
migraine. More often, the improvement occurs with the reduc-
tion of the frequency and intensity, and a more prompt response 
to the medication. Less often, a complete disappearance, wors-
ening or onset of the crisis for the first time is observed. Non-
pharmacological therapies (see treatment of migraine without 
aura) are recommended during pregnancy and may be possibly 
the only one required in low-intensity crises.
If there is a need for pharmacological treatment, it is nec-
essary to weigh the risks to the fetus. It should be noted, how-
ever, the weak scientific evidence regarding the efficacy and 
maternal-fetal safety.
Among the analgesics, the isolated paracetamol or in 
combination with codeine can be used for the remission of 
the migraine crisis of pregnant women.
The NSAIDs ibuprofen, naproxen and indomethacin 
can be administered only during the first and second quar-
ters, belonging to the category B of the   Food and Drug 
Administration (FDA) fetal risk classification, for use in this 
period. They are not recommended, however, in the last 
quarter for increasing the risk of bleeding during delivery, 
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fetal closure of the ductus arteriosus and fetal pulmonary ar-
terial hypertension (category D).
In pregnancy migraine crises of high intensity and that are 
accompanied by nausea and vomiting, chlorpromazine (risk 
category C), promethazine (risk category B), 10 mg metoclo-
pramide (risk category B), 8 mg ondansetron IV up to 3 doses 
a day (risk category B) can be used, which may be combined 
with NSAIDs or opioids (risk category B) (Tables 4 and 5).
Triptans can be used when the benefits outweigh the risks. 
The use of domperidone is not recommended and the use of er-
got derivatives is prohibited (risk categories D and X, respectively).
Usually, there is no worsening of a migraine crisis during 
lactation. There is little evidence regarding serum concen-
trations in infants whose mothers were exposed to drugs for 
treating migraine crises24 (Table 6).
migraines and menopause
About 2/3 of women with migraine stop having migraine 
crises after natural menopause. The treatment of migraine cri-
ses in this stage does not differ from that performed during 
other women’s life periods. The frequency of migraine crises is 
higher in women who have hormone replacement therapy.
Figure 1. Recommended algorithm for the treatment of menstrual migraine crises19.
 
Treatment algorithm of menstrual migraine crisis
 
Menstrual migraine 
Plain menstrual migraine  Migraine related to 
menstruation  
5 to 7 days 
Perimenstrual 
Miniprophylaxis 
Symptomatic treatment
1. Common anagelsics
2. NSAIDs
3. Triptans
4. Ergotamiinics 
 
Hormonal Non-hormonal 
1. NSAIDs
2.Triptans
 
 
Figure 2. Therapeutic approach of menstrual migraine crises with emphasis on prevention.
Therapeutic strategies for the menstrual migraine. 
Highlight to prevention and treatment
Non-frequent crises?
Yes
Yes
No
Acute or abortive therapy Reduced response to the acute therapy/long period
Predictable?
Consider 
miniprophylaxis
Consider long-term 
prophylaxis
No
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Hormone replacement with estrogen in menopausal 
women can induce migraine with aura. The auras can occur 
“again” or there may be an increased frequency of pre-existing 
auras. Women with continuous hormone replacement have 
fewer crises than those with intermittent replacement25
migraine in children and adolescents
Migraine in children and adolescents has particular clini-
cal and therapeutic characteristics. With respect to clinical 
manifestations in the child, crises are brief, and often, are not 
accompanied by a headache, as it occurs in the childhood 
episodic syndromes.
In relation to therapeutic aspects, the relief with sleep 
and rest, the high rate of response to placebo and the 
prominence of autonomic symptoms give rise for an indi-
vidualized approach.
The gold standard of migraine diagnosis in children is 
clinical and longitudinal, which is why a follow up with a 
dairy is always recommended.
Symptomatic medication should be used as soon as pos-
sible, and can be repeated when required. It should not be used 
more often than two days per week. The competence to carry 
Figure 3. Therapeutic approach of migraine crisis in women according to the III Beta version of the International Classification of 
Headache Disorders19.
 
Menstrual migraine Non-menstrual migraine 
Usually with no aura. 
Occurs -2 to +3 and +/- 
other periods of the 
month, predictive 
With or without aura N 
associated w/menstruation
Not frequent/difficult to 
predict, short episodes (<1d)
With or without aura N 
associated w/menstruation
Frequent (>2x/week)
Long episodes (2-3 days)
Acute treatment, if required,
 simple analgesics 
(NSAIDs, Acetaminophen 
or combined Ergotics, 
Triptans
Acute treatment, if required, 
simple analgesics 
(NSAIDs, Acetaminophen 
or combined Ergotics, 
Triptans
Acute treatment, if required, 
simple analgesics 
(NSAIDs, Acetaminophen 
or combined Ergotics, 
Triptans
Inadequate response 
(intense, recurrent, 
persistent menstrual 
migraine)
Miniprophylaxis 
Triptans – start
2 days before menstruation onset, for 5-6 days
360 mg chelated Magnesium
 
Inadequate response 
Urgent therapy (rescue)
Corticoids
Opioids
 
Inadequate response 
Daily preventive therapy
Anticonvulsants
ß-blockers
Tricyclic Antidepressants
Calcium ++ Channel Blockers
 
Migraine in the Woman
Table 1. Pharmacological treatment in the menstrual 
migraine crisis20.
Symptomatic Treatment Miniprophylaxis
Strong Evidence of 
Effectiveness* in the NSAIDs
Menstrual Migraine
NSAIDs
Mefenamic acid 500 mg 3 x d Naproxen sodium 550 mg 2 x d
Nimesulid 100 mg 2-3 x d Minerals and Supplements
Triptans Magnesium 360 mg/d
Naratriptan 2.5 mg
Vitamin E 400 IU/d 
(especially for photophobia, 
phonophobia and nausea)
Rizatriptan 10 mg Triptans
Sumatriptan 50-100 mg Naratriptan 1 mg 2xd
Zolmitriptan 2.5 mg
Sumatriptan 25mg 3xd
Hormones
Percutaneous estradiol Gel 1.5 mg 
(-5 to +2 of menstruation)
Estradiol patch 100µ 
(-4 to +4 of menstruation)
Limited evidence or clinical 
suggestive experience 
of the menstrual migraine 
efficacy
NSAIDs (others)
Ketoprofen 25-50 mg 3 x d
Magnesium 360 mg/d
Mefenamic Acid 500 mg 3-4xd
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and use the medication at school without a responsible adult 
aid should be considered to meet the demand of early use.
Initially, the use of simple analgesics is recommended, 
such as paracetamol and dipyrone (no restriction on age), 
and NSAIDs (ibuprofen – use recommended over 6 months, 
and naproxen - over 2 years). Triptans are released for use 
as of 12 years old. Sumatriptan nasal spray and oral rizatrip-
tan are proven effective. The effectiveness of the sumatriptan 
association with naproxen sodium was demonstrated in a 
study. Naratriptan is useful in migraine miniprophyilaxis as-
sociated with menstruation in adolescents.
In refractory and emergency crises, considering the use 
of EV chlorpromazine or dexamethasone (use released over 2 
years old, but not indicated in the leaflet). The use of opioids 
is not recommended.
The presence of gastroparesis during a migraine crisis 
justifies the use of prokinetic drugs, which must always be 
used with caution, because of their potential extrapyramidal 
Table 2. List of drugs indicated for the acute treatment of menstrual migraine crisis.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Naxoprene sodium 550 mg 2 x/day, starting two days before date of menstruation (expected) for 5 to 7 days or 500 mg 2x/day, starting 7 
days before menstruation to day 6 of the cycle (prophylactic - Level I)
Ibuprofen: 200-400mg - 2-3x/day, starting 7 days before menstruation, to day 6 of the cycle (prophylactic - Level I)
Ketoprofen: 25-50mg – 3x/day, starting 7 days before menstruation to day 6 of the cycle (prophylactic – Level I)
Mefenamic acid: 500 mg – 3-4x/day, starting 2 to 3 days before menstruation to its end (preventive – Level II)
Tolfenamic acid, other NSAIDs, selective inhibitors of cyclooxygenase-2 (COX2) (Celecoxib) may also be used.
Use of NSAIDs does not exclude triptans employment for acute crises that may rise.
Triptans and ergotaminics
Sumatriptan: 25 mg 3x/day – 2 to 3 days before headache onset, for 5 days (preventive – Level I)
Naratriptan: 1 mg (level I) to 2.5 mg (low evidence) – 2x/day – 2 days before headache onset, for 5 days
Triptans and ergominics exclude triptans for crises, but not the use of anti-inflammatory drugs. 
Minerals and supplements
Magnesium: 360 mg, chelated a day, from day 15 after the menstruation onset to the following cycle
Vitamin E: 400 UI a day, for 5 days (-2 to +3 from the menstruation onset)
Table 3. Hormonal treatment for menstrual migraine.
Estrogen gel
Percutaneous estradiol gel: 1.5 mg, two days before menstruation for seven days (evidence level II). -5 to 2 days after the beginning of 
menstruation (1)
Estradiol transdermal patch (TD) 100 µg every two days, for five to seven days (level of evidence II) (three patches), the first three days 
before menstruation, the second at the first day of menstruation, and the third, two days after the menstruation. If the woman is using 
contraceptive pills, a patch on pill 20, one on day 23 of the interval and one on day 26 of the interval (2); or a patch on pill 21 and one on 
day 25 of the interval (two patches).
Table 5. Risk factors for some drugs (Food and Drug 
Administration (FDA))23.
Pregnancy Lactation
Simple analgesics
Aspirin C (D) Warning
Acetaminophen B Warning
Caffeine B Compatible
Dipyrone C Compatible
NSAIDs
Ibuprofen B (D) Compatible
Indomethacin B (D) Compatible
Naproxen B (D) Compatible
Narcotics
Codeine C (D) Compatible
Meperidine B (D) Compatible
Tramadol C Contraindicated
Ergotamine and 
serotonergic 
agonists
Ergotamine X Contraindicated
Dihydroergotamine X Contraindicated
Sumatriptan C Probably compatible
Corticosteroids
Dexamethasone C Probably compatible
Prednisone B Probably compatible
Neuroleptics
Chlorpromazine C Warning
Promethazine C 1st QuarterB 2nd and 3rd Quarter Probably compatible
Haloperidol C Warning
Metoclopramide B Warning
Table 4.  Food and Drug Administration (FDA) drug risk category23.
Category Risk
A Controlled studies in humans show no risks
B No evidence of risk in humans, but there are no controlled human studies
C Risk in humans has not been proven
D Presence risk of evidence in humans, in animal and/or human experiments
X Contraindicated during pregnancy
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side effects; give preference to domperidone, which has lower 
rates of these reactions.
The stratified therapeutic strategy is less used in children 
than in adults, because of crises short duration (sometimes 
less than one hour) and to the difficulty in assessing pain in-
tensity at the beginning of the crisis.
Besides being medicated, the patient must be emotional-
ly supported by his/her parents and oriented to seek rest and 
sleep, measures that often promote significant relief.
Patients and their parents should additionally be informed 
about the crises triggering and aggravating factors, such as 
prolonged fasting, irregular sleep, certain foods and stress.
The literature reviewed shows a significant recent in-
crease in the number of studies on the treatment of migraine 
crises in children and adolescents. However, the clinical tri-
al designs in headache in children and adolescents did not 
follow the advances made in the protocols for adults, hav-
ing not yet been remedied the bias of the high placebo effect 
and the small number of responders. Where possible, drugs 
with indication in the leaflet should be preferred. If there is 
no available evidence, or in the first-line treatment failure, se-
lect a drug with proven efficacy in studies with adults and 
that is safe for children.
Medications reported in the literature and suggested in 
this consensus as useful in migraine crisis in children and ad-
olescents, are shown in Table 6.
tReAtment of miGRAine in emeRGenCy
Most patients who come to the emergency ward with a 
migraine crisis, do so because of intense, prolonged or refrac-
tory crises to home care. Before starting treatment, it is es-
sential to set the diagnosis and identify the drugs used before 
the assistance, including their doses. Presence of associated 
symptoms should be investigated, such as nausea, vomit-
ing, photophobia and phonophobia, focal and/or systemic 
neurological symptoms. The patient must be assisted in a 
place that allows resting in a dark and quiet environment. 
Table 6. Drugs used for migraine crisis in children and adolescents.
Drug Age Dose Route
Paracetamol No restriction 15 mg/kg/doseUp to 6 doses/day PO
Ibuprofen > 6 months 10 mg/kg/doseUp to 4 doses/days PO 
Naproxen and naproxen sodium > 2 years 2.5-5 mg/kg/doseUp to 4 doses/day PO
Acetylsalicylic acida > 12 years 7-10 mg/kg/doseUp to 6 doses/day PO
Dipyrone
< 6 years
6-12 years
> 12 years
6-10 mg/kg/dose
Up to 1 g/day
Up to 2 g/day
Up to 3 g/day
PO
IR
IM
EV
Metoclopramide b > 1 year 0.1-0.2 mg/kg/doseUp to 3 doses/day
PO
IM
EV
IR
Domperidone > 1 year 0.3 mg/kg/doseUp to 3 doses/day PO 
Sumatriptanc > 12 years> 18 years
10 mg
10-20 mg IN
Zolmitriptan > 12 years 2.5 mg/dose PO 
Rizatriptan > 12 years 5-10 mg/dose PO 
Naratriptan > 12 years 2,5 mg/dose PO
Sumatriptan in combination with naproxene or 
naproxene sodium > 12 years
25-50 mg/dose
250-500 mg/dose
275-550 mg/dose
PO
Isometheptene (association) > 1 year 1 drop/kg/dose PO
Chlorpromazine d > 2 years
0.25 mg/kg/dose
up to 6 doses
0.5 mg/kg/dose
up to 4 doses
PO
EV
Dexamethasone > 2 years 0.25 mg/kg/doseup to 4x day EV
abelow 12years old, risk of Reye syndrome; buse in children less than 1 year old is contraindicated; use not recommended to children and adolescents between 
1 and 18 years; cthere is no evidence of efficacy for use of sumatriptan PO (3 studies –  Class I evidence); dmedication indicated for a refractory crisis, although 
not indicated in the national drug information handbook (“off label”).
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In Figure 4, we can find a flowchart that may be used in the 
treatment of migraine crisis.
It is important to pay attention to the warning signs (red flags):
Red flags
• Headache of sudden onset (reaches maximum 
intensity in up to 1 minute);
• First or worst headache ever experienced;
• Subacute progression (days to weeks) with increasing 
intensity and/or frequency;
• Standard change or emergence of new headache in 
migraine patient;
• New headache in patients aged from 50 years;
• Headache in patients with systemic symptoms ( fever, 
weight loss, purulent nasal discharge, sudden high 
blood pressure, thickening of the superficial temporal 
arteries etc.);
• Headache in patients with a history of HIV or cancer;
• Headache in patients with glaucoma or other acute 
ocular disorders;
• Persistent or prolonged aura;
• Headache that appears or disappears with 
postural change;
• Headache in patients with a history of seizures or 
recent CET;
• Abnormalities in the neurological examination 
(including altered consciousness, altered language, 
altered ocular motility, altered visual field and altered 
motor and sensory functions, as well as papilledema 
and meningeal irritation signs);
• Fixed Handedness or exclusively occipital location;
• Absence of improvement with proper treatment;
• Headache triggered by coughing, physical exercise, 
sexual activity or Valsalva maneuver.
In the presence of red flags, apply the appropriate addi-
tional examination:
• Skull and or sinuses computed tomography, according 
to the indication of each case;
• Cranioencephalic MRI, including appropriate 
sequences to each case;
• Lumbar puncture with complete examination of 
cerebrospinal fluid, according to the indication of 
each case;
• Laboratory and/or radiological exams on suspicion of 
systemic diseases;
• There is no indication for electroencephalogram or 
sinus radiography in this context.
It must be remembered that for the headache diagnosis 
we must use current diagnostic criteria - ICHD-3 Beta, 2013.
treatment with drugs
Table 7 shows treatment options according to the mi-
graine crisis characteristic.
Comments:
a) Intravenous hydration is an important part of the 
migraine management in an emergency for two reasons: 
dehydration inherent to the disease and to prevent pos-
tural hypotension induced by chlorpromazine, if that will 
be used.
b) The use of intravenous dexamethasone in prolonged 
migraine crisis appears to reduce the recurrence rate within 
72 hours.
c) Although there is evidence supporting the use of tra-
madol, the prescription of opioids in the emergency room 
is not recommended, due to the risk of inducing a migraine 
chronicity and for the high rate of side effects.
Characterization of favorable response
• Full or significant relief of pain (allows return to 
daily activities);
• Full or significant relief (allows return to daily 
activities) of nausea, vomiting, discomfort and/or 
malaise, as well as any other associated symptoms;
• Reassure that the patient and his family are aware 
and informed on the diagnosis and feel secure as the 
conduct adopted.
instructions at discharge
• Recommend medical consultation for an outpatient 
follow-up and treatment;
• Prescribe treatment for recurrence of headache;Figure 4. Flow chart for migraine crisis treatment.
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• Calm down the patient and family assuring them on 
the goodness of migraine crisis;
• Guide for a return in case of emergency:
• Headache return, worsening or change of pattern;
• Fever;
• Vomiting or difficulty to swallow liquids;
• Dizziness, vertigo, imbalance or difficulty in walking;
• Visual, motor or language disorders;
• Other abnormalities that may worry.
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Table 7. Treatment with drugs.
Medications already used None Common analgesics Ergotics/isometheptene Triptans
Options
Sumatripthane SC
Dipyrone  IV
NSAID IV
Sumatripthane SC
Dipyrone  IV
NSAID IV
Dipyrone IV
NSAID IV
Dipyrone IV
NSAID IV
If nausea, vomiting AntiemeticsHydration
Antiemetics
Hydration
Antiemetics
Hydration
Antiemetics
Hydration
If refractory crisis Dopamine antagonistsValproate sodium IV
Dopamine antagonists
Valproate sodium IV
Dopamine antagonists
Valproate sodium IV
Dopamine antagonists
Valproate sodium IV
ConClusion
In conclusion, in this article a group of experts in the treat-
ment of headache of the Brazilian Headache Society and the 
Scientific Department of Headache of the Brazilian Academy 
of Neurology, through a consensus, developed strategic mea-
sures to treat a migraine crisis in both child and adult. A partic-
ular emphasis was given to the treatment of migraine in wom-
en, including pregnancy, lactation and perimenstrual period.
